HLUN B Stock Overview
A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
H. Lundbeck A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 38.86 |
| 52 Week High | DKK 39.82 |
| 52 Week Low | DKK 30.96 |
| Beta | 0.16 |
| 11 Month Change | 2.97% |
| 3 Month Change | 16.98% |
| 1 Year Change | 19.79% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.57% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely
Jun 05
H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70
Mar 07H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70
Feb 22H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models
Feb 10Shareholder Returns
| HLUN B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 0.4% | 0.3% | 0.9% |
| 1Y | 19.8% | 21.0% | 39.2% |
Return vs Industry: HLUN B underperformed the Danish Pharmaceuticals industry which returned 21% over the past year.
Return vs Market: HLUN B underperformed the Danish Market which returned 39.2% over the past year.
Price Volatility
| HLUN B volatility | |
|---|---|
| HLUN B Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in DK Market | 9.8% |
| 10% least volatile stocks in DK Market | 2.7% |
Stable Share Price: HLUN B has not had significant price volatility in the past 3 months.
Volatility Over Time: HLUN B's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1915 | 5,681 | Charl van Zyl | www.lundbeck.com |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.
H. Lundbeck A/S Fundamentals Summary
| HLUN B fundamental statistics | |
|---|---|
| Market cap | DKK 37.46b |
| Earnings (TTM) | DKK 2.42b |
| Revenue (TTM) | DKK 20.16b |
16.0x
P/E Ratio1.9x
P/S RatioIs HLUN B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLUN B income statement (TTM) | |
|---|---|
| Revenue | DKK 20.16b |
| Cost of Revenue | DKK 4.45b |
| Gross Profit | DKK 15.70b |
| Other Expenses | DKK 13.29b |
| Earnings | DKK 2.42b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | 2.44 |
| Gross Margin | 77.91% |
| Net Profit Margin | 11.99% |
| Debt/Equity Ratio | 16.6% |
How did HLUN B perform over the long term?
See historical performance and comparison